KDX1 Antibody
Description
Introduction to KDX1
KDX1 is a gene identified in Saccharomyces cerevisiae (yeast) as part of the osmotic stress response mediated by the High Osmolarity Glycerol (HOG) pathway. It is transcriptionally regulated by the MAP kinase Hog1, which activates downstream targets under hyperosmotic conditions .
Transcriptional Regulation
KDX1 is significantly upregulated during osmotic stress. Key findings include:
-
Fold Change: KDX1 expression increased by 26.33-fold in yeast strains expressing an active Hog1 variant compared to controls .
-
Functional Context: KDX1 is co-regulated with other stress-response genes like STL1 (87.68-fold change) and GPD1 (18.19-fold change), which are critical for glycerol synthesis and osmotic balance .
Role in Stress Adaptation
While KDX1’s exact molecular function remains unclear, its strong induction under stress suggests involvement in:
-
Cellular osmoregulation.
-
Coordination with other Hog1 targets to restore homeostasis.
Table 1: Top Induced Genes in Hog1-Activated Yeast
| Gene Name | Fold Change | Associated Pathway |
|---|---|---|
| STL1 | 87.68 | Glycerol transport |
| KDX1 | 26.33 | Stress response |
| GPD1 | 18.19 | Glycerol biosynthesis |
Source: Transcriptomic analysis of hog1Δpbs2Δ yeast expressing active Hog1 .
Table 2: Comparative Expression of Stress-Response Genes
| Gene | Function | Fold Change |
|---|---|---|
| HSP12 | Chaperone activity | 47.21 |
| GRE2 | Detoxification | 13.01 |
| KDX1 | Unknown | 26.33 |
Antibody Applications and Limitations
Although no commercial KDX1 antibodies are explicitly documented, antibodies targeting yeast stress-response proteins are typically used for:
-
Western Blotting: To quantify KDX1 expression under varying stress conditions.
-
Localization Studies: To map KDX1’s subcellular distribution during osmotic shock.
Challenges:
-
Lack of structural or functional characterization of KDX1 limits epitope prediction for antibody design.
-
Cross-reactivity risks with homologous proteins in yeast or other species.
Future Research Directions
-
Mechanistic Studies: Elucidate KDX1’s interaction partners and enzymatic activity.
-
Antibody Development: Generate monoclonal antibodies validated via knock-out strains.
-
Therapeutic Potential: Explore homologs in pathogenic fungi for antifungal drug targeting.
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
KEGG: sce:YKL161C
STRING: 4932.YKL161C
Q&A
What experimental strategies are used to isolate and characterize KDX1 antibodies from Kawasaki disease patients?
Methodological Answer:
KDX1 antibodies are typically isolated from peripheral blood plasmablasts of acute-phase KD patients using single-cell sorting and monoclonal antibody (mAb) cloning techniques . Key steps include:
-
Plasmablast Enrichment: Peripheral blood mononuclear cells (PBMCs) are collected 1–3 weeks post-fever onset, a period when antigen-specific plasmablasts dominate (~70% of circulating plasmablasts) .
-
Single-Cell Sequencing: V(D)J regions of immunoglobulin heavy and light chains are amplified from individual plasmablasts and cloned into expression vectors .
-
Antigen Screening: Recombinant mAbs are tested against putative KD antigens (e.g., synthetic KD peptide) using ELISA and immunohistochemistry (IHC). For example, 5/60 mAbs from KD patients showed specific binding to the KD peptide (OD450 > 2.0 vs. scrambled peptide controls) .
Validation:
-
IHC: Antibodies like KD4-2H4 bind intracytoplasmic inclusion bodies in KD bronchial epithelium (3/3 KD lung tissues vs. 0/3 controls) .
-
Cross-Reactivity Assays: Non-reactivity to insulin, DNA, or BSA confirms specificity .
How do researchers confirm the specificity of KDX1 antibodies for KD-associated epitopes?
Methodological Answer:
Specificity is validated through a multi-platform approach:
-
Epitope Mapping: Phage display libraries or alanine scanning mutagenesis identify critical residues in the KD peptide recognized by KDX1 antibodies .
-
Competitive ELISA: Pre-incubation with soluble KD peptide reduces antibody binding by >90%, while scrambled peptides show no inhibition .
-
Structural Biology: Cryo-EM or X-ray crystallography validates epitope-paratope interactions. For instance, RFdiffusion-designed antibodies achieve <2 Å RMSD between predicted and observed CDR loop conformations .
Data Interpretation:
-
False Positives: 22/60 mAbs showed weak IHC binding to inclusion bodies but no peptide reactivity, suggesting cross-reactivity with unrelated epitopes .
-
Temporal Dynamics: Plasmablasts collected >20 days post-onset often lose specificity, necessitating early sampling .
How can researchers reconcile discrepancies between immunohistochemical and ELISA data for KDX1 antibodies?
Methodological Answer:
Contradictions arise due to:
-
Epitope Conformation: The KD peptide may adopt different structures in solution (ELISA) vs. tissue (IHC). Circular dichroism or NMR can assess structural preservation .
-
Post-Translational Modifications: Tissue-specific glycosylation or phosphorylation of the native antigen may alter antibody binding .
Resolution Strategies:
-
Antigen Retrieval: Proteolytic treatment of formalin-fixed tissues restores conformational epitopes .
-
Surface Plasmon Resonance (SPR): Measures binding kinetics to native vs. recombinant antigens (e.g., KD4-2H4 shows KD = 10 nM for tissue-extracted antigen vs. 100 nM for synthetic peptide) .
What computational tools enable the design of KDX1-like antibodies with enhanced specificity?
Methodological Answer:
De novo antibody design pipelines integrate:
-
RFdiffusion Networks: Generate VHH or scFv sequences targeting user-defined epitopes (e.g., influenza hemagglutinin with atomic-level accuracy) .
-
Affinity Maturation: OrthoRep-directed evolution improves binding affinity from µM to nM ranges while preserving epitope specificity .
Case Study:
-
TcdB Toxin scFv: A designed scFv achieved 1.2 nM affinity for Clostridium difficile toxin B, with cryo-EM confirming all six CDR loops matched computational predictions (RMSD = 0.8 Å) .
How do clonal expansion patterns in KD plasmablasts influence antibody functional diversity?
Methodological Answer:
Single-cell RNA sequencing reveals:
-
Oligoclonal Expansion: 82% of KD patients show clonally expanded plasmablasts producing inclusion body-specific antibodies .
-
Light Chain Pairing: Synthetic antibodies with non-cognate light chains lose specificity, underscoring the importance of natural VH-VL pairing .
Experimental Design Considerations:
-
Longitudinal Sampling: Track plasmablast clonality at multiple timepoints to capture dynamic responses .
-
Bulk vs. Single-Cell Analysis: Single-cell approaches resolve heterogeneity missed by bulk sequencing (e.g., rare clones constituting <1% of the repertoire) .
